Aktis Oncology, Inc.

Aktis Oncology, Inc. (AKTS) priced its initial public offering on Jan 9, 2026 at $18.00 per share, within its $16.00–$18.00 range, raising $317.7M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $911.7M. J.P. Morgan was lead-left underwriter, joined by BofA Securities, Leerink Partners and TD Cowen. Davis Polk advised the underwriters.

Status

IPO

Ticker

AKTS

Exchange

Nasdaq Global Select

Priced

Jan 9, 2026

IPO price

$18.00

Price range

$16.00–$18.00

Raised

$317.7M

Market cap at IPO price

$911.7M

First filed

Dec 19, 2025

Underwriters

J.P. Morgan, BofA Securities, Leerink Partners and TD Cowen

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.